comparemela.com

Latest Breaking News On - Diagnostic solutions segment - Page 4 : comparemela.com

Stevanato Group Reports First Quarter 2022 Financial Results

10.05.2022 - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first .

United statesUnited kingdomFranco moroFranco stevanatoExchange commission onCompany investor relationsSolutions segmentDevelopment expensesEuropean unionStevanato groupStevanato group board of directorsDiagnostic solutionsChief executive officerDiagnostic solutions segmentEngineering segmentStevanato group board

Stevanato Group Reports Record 2021 Revenue of €843 9 million

08.03.2022 - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth .

United statesUnited kingdomFranco moroFranco stevanatoItalian tax agencyCompany investor relationsSolutions segmentCompany annual report on formDevelopment expensesExchange commissionStevanato groupChief executive officerDiagnostic solutions segmentExecutive chairmanEuropean timeFinancial information

Stevanato Group S p A : Stevanato Group Reports Record 2021 Revenue of €843 9 million

Establishes Full Year 2022 Guidance Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology

United statesUnited kingdomFranco moroFranco stevanatoItalian tax agencyCompany investor relationsSolutions segmentCompany annual report on formDevelopment expensesExchange commissionStevanato groupEstablishes full yearFull year highlightsChief executive officerDiagnostic solutions segmentExecutive chairman

vimarsana © 2020. All Rights Reserved.